Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.82 |
| ▸ | NR2E3 | Q9Y5X4 | 4/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 3/20 | 0.58 |
| ▸ | MMP9 | P14780 | 3/20 | 0.58 |
| ▸ | MMP8 | P22894 | 3/20 | 0.58 |
| ▸ | MMP13 | P45452 | 3/20 | 0.58 |
| ▸ | PRSS12 | P56730 | 3/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249930 | 0.93 | DGAT1 (0.85) | DGAT1NR2E3CHEK2HDAC3HDAC1 | |
| SCHEMBL1250343 | 0.90 | DGAT1 (0.80) | DGAT1NR2E3CHEK2MMP2MMP9 | |
| SCHEMBL1248774 | 0.90 | DGAT1 (1.00) | DGAT1NR2E3CHEK2HDAC6PRSS12 | |
| SCHEMBL1250626 | 0.89 | DGAT1 (0.77) | DGAT1NR2E3CHEK2HDAC6 | |
| SCHEMBL1251539 | 0.88 | DGAT1 (0.84) | DGAT1NR2E3CHEK2HDAC3HDAC6 | |
| SCHEMBL1251547 | 0.88 | DGAT1 (0.84) | DGAT1NR2E3CHEK2KDR | |
| SCHEMBL1250956 | 0.87 | DGAT1 (0.78) | DGAT1NR2E3CHEK2KDR | |
| SCHEMBL1249997 | 0.87 | DGAT1 (0.82) | DGAT1NR2E3CHEK2KDR | |
| SCHEMBL1250221 | 0.87 | DGAT1 (0.85) | DGAT1NR2E3CHEK2HDAC6KDR | |
| SCHEMBL1251450 | 0.86 | DGAT1 (0.77) | DGAT1NR2E3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20100016387-A1 | METHOD OF TREATMENT | BOSE AVIRUP | 2010-01-21 | — | — | US | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885NR2E3 1657/4885CHEK2 4427/4885 |
| US-20100016387-A1 | METHOD OF TREATMENT | DGAT1, DGAT2, DGKA | DGAT1 1/4885NR2E3 3620/4885CHEK2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.